SEC61G and central nervous system cancer: Using Oncomine data, we observed that SEC61G was upregulated in almost all cancer types, compared to normal tissues (p < 0.001, |log2 fold change| > 1.5 in all gene ranks), including breast cancer, kidney cancer, brain and central nervous system cancer, and head and neck cancer (Figure 1A).